Key result
Real-world deutetrabenazine is linked to reduced tardive dyskinesia severity and improved patient-reported quality of life.
Why the study?
Does deutetrabenazine reduce tardive dyskinesia severity and improve quality of life in patients with tardive dyskinesia?
Does deutetrabenazine reduce tardive dyskinesia severity and improve quality of life in patients with tardive dyskinesia?
Real-world use of deutetrabenazine is associated with reduced tardive dyskinesia severity and improved quality of life based on patient-reported outcomes.
May support deutetrabenazine consideration in tardive dyskinesia; hypothesis-generating pending randomized confirmation.
To evaluate the real-world effectiveness of deutetrabenazine (DTBZ) treatment on the multidimensional impact of tardive dyskinesia (TD), as assessed by patient-reported outcome (PRO) scales.
No takes yet. Share an insight, caveat, or question.
Finkbeiner et al. (2026) studied this question. Deutetrabenazine reduces tardive dyskinesia severity and improves quality of life based on patient-reported outcomes in real-world settings.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: